The Food and Drug Administration’s recent decision to approve a new generic abortion pill has elicited strong backlash from conservative groups. Their anger reflects broader tensions over the future of medication abortion and access to reproductive health care.

The U.S. Food and Drug Administration, operating under Donald Trump’s presidency, approved a new generic abortion pill. This decision arrives as abortion medications face increased scrutiny nationwide, highlighting the ongoing debate over reproductive rights.

The FDA has approved Inluriyo (imlunestrant), an oral therapy for advanced breast cancer that targets estrogen receptor-1 mutations. A phase 3 clinical trial found that patients receiving the treatment had improved progression-free survival compared to those on a different investigational regimen.

SpringWorks Therapeutics’ CEO, Saqib Islam, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The announcement follows the company’s recent FDA approval of their first therapy, OGSIVEO®, marking a significant milestone in their mission to treat severe rare diseases and cancer.